Zacks Investment Research
16 Nov 2026, 13:50 UTC · 11h ago
Here's How Abbott's EP Business Is Shaping Up for the Rest of 2026
Impact · against what's priced in
The update on Abbott's EP business confirms existing growth expectations without providing a catalyst for a valuation re-rating. While PFA adoption and the TactiFlex Duo approval are positive, they align with the medical device growth premiums already reflected in the current price.
- ABT+0.00
Already priced in
- The price assumes
Medical Devices and Diabetes Care growth premium
The 8% growth in Medical Devices and the accelerated adoption of the Volt PFA catheter support the growth premium the market already pays for in the devices segment.
What ABT's price assumes · Sep 12

Top 1 mover · tap to explore



